About us
- >
- About us >
- Information >
- Announcement
2022-09-19
Applied to the US FDA for an Investigational New Drug (IND) application for the Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical ge
We are pleased to announce that on September 19, 2022, our company received notification from the Contract Research Organization (CRO) that our investigational new drug, ENERGI-F703 diabetic foot ulcer topical gel, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).